Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

28 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.
Esfahani K, Miller WH Jr. Esfahani K, et al. N Engl J Med. 2017 May 18;376(20):1989-91. doi: 10.1056/NEJMc1703047. N Engl J Med. 2017. PMID: 28514612 No abstract available.
Programmed Cell Death Ligand 1-Induced Coma From Diffuse Cerebritis.
Desforges P, Esfahani K, Bouganim N. Desforges P, et al. Among authors: esfahani k. J Oncol Pract. 2018 Feb;14(2):134-135. doi: 10.1200/JOP.2017.024992. Epub 2017 Oct 10. J Oncol Pract. 2018. PMID: 29016224 No abstract available.
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.
Esfahani K, Buhlaiga N, Th├ębault P, Lapointe R, Johnson NA, Miller WH Jr. Esfahani K, et al. N Engl J Med. 2019 Jun 13;380(24):2375-2376. doi: 10.1056/NEJMc1903064. N Engl J Med. 2019. PMID: 31189042 No abstract available.
Moving towards personalized treatments of immune-related adverse events.
Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH Jr, Calabrese L. Esfahani K, et al. Nat Rev Clin Oncol. 2020 Aug;17(8):504-515. doi: 10.1038/s41571-020-0352-8. Epub 2020 Apr 3. Nat Rev Clin Oncol. 2020. PMID: 32246128 Review.
A review of cancer immunotherapy: from the past, to the present, to the future.
Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr. Esfahani K, et al. Curr Oncol. 2020 Apr;27(Suppl 2):S87-S97. doi: 10.3747/co.27.5223. Epub 2020 Apr 1. Curr Oncol. 2020. PMID: 32368178 Free PMC article. Review.
Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.
Esfahani K, Hudson M, Batist G. Esfahani K, et al. N Engl J Med. 2020 Jun 11;382(24):2374-2375. doi: 10.1056/NEJMc2002527. N Engl J Med. 2020. PMID: 32521140 No abstract available.
Acute liver failure because of chronic lymphocytic leukemia: case report and review of the literature.
Esfahani K, Gold P, Wakil S, Michel RP, Solymoss S. Esfahani K, et al. Curr Oncol. 2011 Jan;18(1):39-42. doi: 10.3747/co.v18i1.756. Curr Oncol. 2011. PMID: 21331280 Free PMC article.
The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.
Meti N, Esfahani K, Johnson NA. Meti N, et al. Among authors: esfahani k. Cancers (Basel). 2018 Jun 15;10(6):204. doi: 10.3390/cancers10060204. Cancers (Basel). 2018. PMID: 29914088 Free PMC article. Review.
Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression.
Meti N, Petrogiannis-Haliotis T, Esfahani K. Meti N, et al. Among authors: esfahani k. J Oncol Pract. 2018 Aug;14(8):514-516. doi: 10.1200/JOP.18.00177. Epub 2018 Jul 13. J Oncol Pract. 2018. PMID: 30004823 No abstract available.
Endocrine therapy for breast cancer in the primary care setting.
Awan A, Esfahani K. Awan A, et al. Among authors: esfahani k. Curr Oncol. 2018 Aug;25(4):285-291. doi: 10.3747/co.25.4139. Epub 2018 Aug 14. Curr Oncol. 2018. PMID: 30111969 Free PMC article.
28 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback